Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Further support for hippocampal volume as psychosis biomarker

Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes provide further evidence that reduced hippocampal volume is a consistent feature of schizophrenia.

27 Feb 2014

First Edition: February 27, 2014

Today's headlines include a number of stories about Obama past and present administration officials -- notably, former Secretary of State Hillary Clinton and Vice President Joe Biden -- who are stepping up to "sell" people on enrolling in new health law insurance coverage.

27 Feb 2014

Adults with mental illness more likely to be victims of violence, says study

New research shows that almost one-third of adults with mental illness are likely to be victims of violence within a six-month period, and that adults with mental illness who commit violence are most likely to do so in residential settings.

27 Feb 2014

Antidepressant medication shows potential in treating symptoms of agitation that occur with AD

An antidepressant medication has shown potential in treating symptoms of agitation that occur with Alzheimer's disease and in alleviating caregivers' stress, according to a multi-site U.S.- Canada study.

20 Feb 2014

New drug patent may help overcome problems associated with MDR-TB

A chemist based at the University of Copenhagen has just taken out a patent for a drug that can make previously multidrug-resistant bacteria once again responsive to antibiotics.

18 Feb 2014

Common mutations produce typical schizophrenia brain changes

Mutations in dopamine-related genes have a dose-response effect on prefrontal activation during emotional response inhibition in healthy adults, a study shows.

13 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Disorganisation, verbal memory help shape QoL in schizophrenia

Disorganisation and cognition each influence quality of life in people with schizophrenia and are promising targets of interventions to improve functional outcomes, say researchers.

7 Feb 2014

Talking therapy may provide effective alternative to medication for people with schizophrenia

Cognitive therapy may provide an effective alternative to antipsychotic medication for patients with schizophrenia, report researchers.

6 Feb 2014

Cognitive therapy promising for patients who shun antipsychotics

Cognitive behavioural therapy is a promising option for patients with schizophrenia who refuse to take antipsychotics, show the findings of a pilot randomised trial.

6 Feb 2014

10-minute neurocognitive measure valid in schizophrenia

Canadian researchers have developed a 10-minute tool that they claim can “rapidly, easily, and validly” assess global neurocognition in people with schizophrenia.

4 Feb 2014

More antipsychotic medications prescribed to children and adolescents in Germany

Increasing numbers of children and adolescents are being given antipsychotic drugs in Germany, as Christian Bachmann and colleagues found out in a study published in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2014; 111(3): 25 - 40). The authors used routine insurance data of the Barmer GEK statutory health insurance company to analyze antipsychotic prescriptions for this age group from 2005 to 2012.

31 Jan 2014

Psychiatrists urged to monitor metabolic changes in psychosis patients

Japanese psychiatrists are largely aware of the metabolic abnormalities that may arise from antipsychotic treatment, but most do not monitor their patients sufficiently, research shows.

30 Jan 2014

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.

29 Jan 2014

Research reveals new information about the genetic complexity underpinning schizophrenia

The Icahn School of Medicine at Mount Sinai today announced the publication of two papers in the journal Nature that reveal new information about the genetic complexity underpinning schizophrenia. These collaborative studies represent the largest exome sequencing efforts to date to elucidate this mental illness, and together found that the disorder is likely caused by far more rare genetic mutations than previously suspected.

23 Jan 2014

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel therapies for central nervous system diseases, today announced it has initiated COGNITIV AD, a Phase 3 clinical program evaluating its novel alpha-7 (α7) potentiator, encenicline-hydrochloride (EVP-6124), in patients with Alzheimer's disease. The program is being conducted under a Special Protocol Assessment agreement with the FDA.

22 Jan 2014

Basic hospice strategies can make last days of dying inpatients more comfortable and dignified

There is much value in training hospital and nursing home staff in the basics of palliative care to make the last days of a dying patient's life as comfortable and dignified as possible.

22 Jan 2014

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, announced that reported diluted earnings per share equaled $0.07 in the third quarter of fiscal 2014, compared to a reported loss per share of ($0.58) in the third quarter of fiscal 2013. The third quarter of fiscal 2014 included a $45 million charge ($28.2 million net of tax) related to Project Rejuvenate.

21 Jan 2014

More evidence for glutamate dysregulation in schizophrenia

Levels of glutamine, but not glutamate, are elevated in the dorsal anterior cingulate of patients with established schizophrenia, say researchers.

15 Jan 2014

New programme to reduce risk of type 2 diabetes in people with schizophrenia

A group of researchers, led by Professor Richard Holt at the University of Southampton, are to investigate whether people with schizophrenia or first episode psychosis are able to reduce their weight through a structured education programme.

14 Jan 2014

Antipsychotic News and Research

Further support for hippocampal volume as psychosis biomarker

First Edition: February 27, 2014

Adults with mental illness more likely to be victims of violence, says study

Antidepressant medication shows potential in treating symptoms of agitation that occur with AD

New drug patent may help overcome problems associated with MDR-TB

Common mutations produce typical schizophrenia brain changes

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Disorganisation, verbal memory help shape QoL in schizophrenia

Talking therapy may provide effective alternative to medication for people with schizophrenia

Cognitive therapy promising for patients who shun antipsychotics

10-minute neurocognitive measure valid in schizophrenia

More antipsychotic medications prescribed to children and adolescents in Germany

Psychiatrists urged to monitor metabolic changes in psychosis patients

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Research reveals new information about the genetic complexity underpinning schizophrenia

EnVivo Pharmaceuticals starts encenicline Phase 3 study in patients with Alzheimer's disease

Basic hospice strategies can make last days of dying inpatients more comfortable and dignified

Forest Laboratories third quarter net sales increase 24.9% to $846.8 million

More evidence for glutamate dysregulation in schizophrenia

New programme to reduce risk of type 2 diabetes in people with schizophrenia

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News